METHOD FOR PRODUCING SUBSTITUTED ANTHRANILIC ACID DERIVATIVES

Information

  • Patent Application
  • 20150011772
  • Publication Number
    20150011772
  • Date Filed
    February 06, 2013
    11 years ago
  • Date Published
    January 08, 2015
    9 years ago
Abstract
The present invention relates to a process for preparing substituted anthranilic acid derivatives of the formula (I)
Description

The present invention relates to a novel process for preparing substituted anthranilic acid derivatives of the formula (I)




embedded image


in which

    • R1 is optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, or C6-C10-aryl, or is a hetaryl radical of the general formula (II)




embedded image




    • R1 is preferably C1-C3-alkyl, C6-aryl or a hetaryl radical of the general formula (II),

    • R1 is more preferably C1-C2-alkyl or a hetaryl radical of the general formula (II),


      where

    • R8 is C1-C6-alkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, which may optionally be mono- or polysubstituted identically or differently by fluorine or chlorine, or is fluorine, chlorine, cyano, alkylamino, dialkylamino, cycloalkylamino or C3-C6-trialkylsilyl,

    • R8 is preferably fluorine, chlorine or C1-C6-alkyl,

    • R8 is more preferably fluorine or chlorine,

    • Z is CH or N,

    • Z is preferably and more preferably N,


      and

    • Y is hydrogen, fluorine, chlorine, optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, or is cyano, alkylamino, dialkylamino, cycloalkylamino, C3-C6-trialkylsilyl or a radical of the general formula (III)







embedded image


where

    • R9 is C1-C5-alkyl which may optionally be mono- or polysubstituted identically or differently by halogen,
    • R9 is preferably C1-C3 perfluoroalkyl,
    • R9 is more preferably CF3 or C2F5,
    • R2 is an OR5 or NR6R7 radical,
    • R2 is preferably and more preferably OR5,
    • R2 is likewise preferably and more preferably NR6R7,


      where
    • R5, R6 and R7 are each independently hydrogen, C1-C6-alkyl, or C6-C10-aryl,
    • R5, R6 and R7 are preferably each independently hydrogen, C1-C3-alkyl or C6-aryl,
    • R5, R6 and R7 are more preferably each independently hydrogen or C1-C2-alkyl,
    • R3 is hydrogen, optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, C1-C6-alkoxy or C3-C6-cycloalkyl,
    • R3 is likewise halogen,
    • R3 is preferably C1-C5-alkyl,
    • R3 is more preferably methyl, ethyl or tert-butyl,
    • R3 is likewise preferably and more preferably chlorine,
    • R4 is hydrogen, fluorine, chlorine, cyano, optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-alkylamino, di(C1-C4-alkyflamino, C3-C6-cycloalkylamino, (C1-C4-alkoxy)imino, (C1-C4-alkyl)(C1-C4-alkoxy)imino, SF5 or C3-C6-trialkylsilyl,
    • R4 is preferably hydrogen, chlorine or cyano,
    • R4 is more preferably chlorine or cyano,


      characterized in that substituted anthranilic acid derivatives of the formula (IV)




embedded image


in which the R1, R3 and R4 radicals are each as defined above


and

    • X is chlorine, bromine or iodine, preferably bromine or iodine, more preferably bromine,


      are reacted in the presence of a palladium catalyst and optionally of a phosphine ligand simultaneously with carbon monoxide and a compound of the general formula (V)





R5-OH   (V)


in which R5 is as defined above


or a compound of the general formula (VI)





HNR6R7   (VI)


in which R6 and R7 are each as defined above.


The literature already states that it is possible to obtain substituted anthranilic acid derivatives of the formula (I) by reaction of anthranilic acid derivatives of the general formula (VII)




embedded image


with carboxylic acids of the general formula (VIII)





R1-COOH   (VIII)


in the presence of agents which activate the carboxyl group for the desired reaction, for example thionyl chloride, oxalyl chloride, phosgene, methanesulphonyl chloride or toluenesulphonyl chloride (WO 2003/015519; WO 2003/106427; WO 2004/067528; WO 2006/062978; WO 2008/010897; WO 2008/070158; WO 2008/082502; WO 2009/006061; WO 2009/061991; WO 2009/085816; WO 2009 111553; Bioorg. & Med. Chem. Lett. 15 (2005) 4898-4906; Bioorg. & Med. Chem. 16 (2008) 3163-3170).


The known reactions can be illustrated by the following reaction schemes, where R1, R3, R4, R6 and R7 have, for example, the definitions given above:




embedded image




embedded image


These known methods for preparation of substituted anthranilic acid derivatives of the formula (I) require the availability of the corresponding substituted anthranilic acid derivatives of the general formula (VII). These substituted anthranilic acid derivatives of the general formula (VII) are either known or can be prepared by known organic chemistry methods. Some of these substituted anthranilic acid derivatives of the general formula (VII), however, can be prepared only in a complex manner, in multiple stages and at high cost, which can lead to uneconomically high costs for the end products as a result of unavoidable yield losses.


Substituted anthranilic acid derivatives of the formula (I) are of high interest as compounds having known insecticidal efficacy (see, for example, Bioorg. & Med. Chem. Lett. 15 (2005) 4898-4906; Biorg. & Med. Chem. 16 (2008) 3163-3170). Further, it is already known, that substituted anthranilic acid derivatives of the general formula (VII) can be obtained by reacting substituted anthranilic acid derivatives of the general formula (IX) with carbon monoxide in the presence of a palladium catalyst, of a ligand, of a primary amine and a base (WO 2012/103436). However, it is not known whether anthranilic acid amides of the general formula (IV) can be used correspondingly.


It is therefore an object of the present invention to provide a novel, more economically viable process for preparing substituted anthranilic acid derivatives of the formula (I).


The object was achieved according to the present invention by a process for preparing anthranilic acid derivatives of the general formula (I), characterized in that substituted anthranilic acid derivatives of the general formula (IX)




embedded image


in which X, R3 and R4 are each as defined above


are reacted with acids of the general formula (VIII) to give the substituted anthranilic acid derivatives of the formula (IV)




embedded image


and the latter are then reacted in the presence of a palladium catalyst and optionally of a phosphine ligand simultaneously with carbon monoxide and a compound of the general formula (V)





R5-OH   (V)


in which R5 is as defined above


or a compound of the general formula (VI)





HNR6R7   (VI)


in which R6 and R7 are each as defined above


to give the substituted anthranilic acid derivatives of the general formula (I).


The process according to the invention can be illustrated by the following scheme:




embedded image


The present invention likewise provides novel compounds of the general formula (IV)




embedded image


in which the R1, R3, R4 and X radicals are each as defined above.


Preference is given to compounds of the general formula (IV) in which

    • R1 is optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, or C6-C10-aryl, or is a hetaryl radical of the general formula (II)




embedded image


where

    • R8 is optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, or is fluorine, chlorine, cyano, alkylamino, dialkylamino, cycloalkylamino or C3-C6-trialkylsilyl, preferably fluorine, chlorine or C1-C6-alkyl, more preferably fluorine or chlorine,
    • Z is CH or N, preferably N,


      and
    • Y is hydrogen, fluorine, chlorine, optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, or is cyano, alkylamino, dialkylamino, cycloalkylamino, C3-C6-trialkylsilyl or a radical of the general formula (III)




embedded image


in which

    • R9 is C1-C5-alkyl which may be mono- or polysubstituted identically or differently by halogen,
    • R9 is preferably C1-C3-perfluoroalkyl,
    • R9 is more preferably CF3 or C2F5,
    • R3 is chlorine,
    • R3 is likewise methyl,
    • R4 is chlorine or cyano,


      and
    • X is bromine or iodine.


Particular preference is given to compounds of the general formula (IV) in which

    • R1 is a hetaryl radical of the general formula (II)




embedded image


where

    • R8 is fluorine or chlorine,
    • Z is N,


      and
    • Y is hydrogen, fluorine, chlorine or a radical of the general formula (III)




embedded image


where

    • R9 is CF3 or C2F5,
    • R3 is methyl,
    • R4 is chlorine or cyano,


      and
    • X is bromine


Examples of the particularly preferred compounds of the general formula (IV) include:


N-(2-bromo-4-cyano-6-methylphenyl)-1-(3-chloropyridin-2-yl)-3-{[5-(trifluoromethyl)-2H-tetrazol-2-yl]methyl}-1H-pyrazole-5-carboxamide


N-(2-bromo-4-chloro-6-methylphenyl)-1-(3-chloropyridin-2-yl)-3-{[5-(pentafluoroethyl)-2H-tetrazol-2-yl]methyl}-1H-pyrazole-5-carboxamide.


General definitions: Alkyl groups substituted by one or more fluorine or chlorine atoms (=fluoro- or chloroalkyl groups) are selected, for example, from trifluoromethyl (CF3), difluoromethyl (CHF2), CCl3, CFCl2, CF3CH2, ClCH2, CF3CCl2.


Alkyl groups in the context of the present invention, unless defined differently, are linear or branched hydrocarbyl groups.


The definition alkyl and C1-C12-alkyl encompasses, for example, the meanings of methyl, ethyl, n-, isopropyl, n, iso-, sec- and t-butyl, n-pentyl, n-hexyl, 1,3-dimethylbutyl, 3,3-dimethylbutyl, n-heptyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl.


Cycloalkyl groups in the context of the present invention, unless defined differently, are cyclic saturated hydrocarbyl groups.


Aryl radicals in the context of the present invention, unless defined differently, are aromatic hydrocarbyl radicals which may have one, two or more heteroatoms selected from O, N, P and S and may optionally be substituted by further groups.


Arylalkyl groups and arylalkoxy groups in the context of the present invention, unless defined differently, are, respectively, alkyl and alkoxy groups which are substituted by aryl groups and may have an alkylene chain. Specifically, the definition arylalkyl encompasses, for example, the meanings of benzyl and phenylethyl, and the definition arylalkoxy, for example, the meaning of benzyloxy.


Alkylaryl groups (alkaryl groups) and alkylaryloxy groups in the context of the present invention, unless defined differently, are, respectively, aryl groups and aryloxy groups which are substituted by alkyl groups, may have a C1-8-alkylene chain and may have, in the aryl skeleton or aryloxy skeleton, one or more heteroatoms selected from O, N, P and S.


Step 1


Anthranilic acid derivatives of the formula (IV) can be prepared as follows:




embedded image


The reaction is performed in the presence of a condensing agent. Suitable agents for this purpose are all agents customary for such coupling reactions. Examples include acid halide formers such as phosgene, phosphorus tribromide, phosphorus trichloride, phosphorus pentachloride, phosphorus oxychloride, oxalyl chloride or thionyl chloride; anhydride formers such as ethyl chloroformate, methyl chloroformate, isopropyl chloroformate, isobutyl chloroformate or methanesulphonyl chloride; carbodiimides such as N,N′-dicyclohexylcarbodiimide (DCC) or other customary condensing agents such as phosphorus pentoxide, polyphosphoric acid, 1,1′-carbonyldiimidazole, 2-ethoxy-N-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ), triphenylphosphine/carbon tetrachloride, bromotripyrrolidinophosphonium hexafluorophosphate, bis(2-oxo-3-oxazolidinyl)phosphine chloride or benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate. It is likewise possible to use polymer-supported reagents, for example polymer-bound cyclohexylcarbodiimide


Preference is given to phosgene, mesyl chloride and thionyl chloride.


Process step 1 can optionally be performed in the presence of an inert organic diluent customary for such reactions. These preferably include aliphatic, alicyclic or aromatic hydrocarbons, for example petroleum ether, hexane, heptane, cyclohexane, methylcyclohexane, benzene, toluene, xylene or decalin; halogenated hydrocarbons, for example chlorobenzene, dichlorobenzene, dichloromethane, chloroform, carbon tetrachloride, dichloroethane or trichloroethane; ethers such as diethyl ether, diisopropyl ether, methyl tert-butyl ether, methyl tert-amyl ether, dioxane, tetrahydrofuran, 1,2-dimethoxyethane, 1,2-diethoxyethane or anisole; ketones such as acetone, butanone, methyl isobutyl ketone or cyclohexanone; nitriles such as acetonitrile, propionitrile, n- or isobutyronitrile or benzonitrile; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylformanilide, N-methylpyrrolidone or hexamethylphosphoramide, or mixtures thereof.


Process step 1 is generally performed in the presence of a base.


Suitable bases are alkali metal hydroxides, for example lithium hydroxide, sodium hydroxide or potassium hydroxide, alkali metal carbonates, for example Na2CO3, K2CO3, and acetates, for example NaOAc, KOAc, LiOAc, and also alkoxides, for example NaOMe, NaOEt, NaOt-Bu, KOt-Bu. Likewise suitable bases are organic bases such as trialkylamines, alkylpyridines, phosphazenes and 1,8-diazabicyclo[5.4.0]undecene (DBU). Preference is given to organic bases such as pyridines, alkylpyridines, for example 2,6-dimethylpyridine, 2-methyl-5-ethylpyridine or 2,3-dimethylpyridine.


Process step 1 of the invention is performed preferably within a temperature range from 20° C. to +100° C., more preferably at temperatures of 30° C. to +80 ° C., more preferably at 30-60° C.


Process step 1 of the invention is generally performed under standard pressure. Alternatively, however, it is also possible to work under vacuum or under elevated pressure in an autoclave.


The reaction time may, according to the batch size and the temperature, be selected within a range between 1 hour and several hours.


Process step 1 can optionally be performed in the presence of a catalyst. Examples include 4-dimethylaminopyridine or 1-hydroxybenzotriazole.


Step 2


Substituted anthranilic acid derivatives of the general formula (1) can be prepared in accordance with process step 2 as follows:




embedded image


The reaction is performed in the presence of a palladium catalyst. The palladium catalysts used in the process according to the invention are palladium(II) salts, for instance palladium chloride, bromide, iodide, acetate or acetylacetonate, which may optionally be stabilized by further ligands, for example alkyl nitriles, or Pd(O) species, for example palladium on activated carbon, Pd(PPh3)4, bis(dibenzylideneacetone)palladium or tris(dibenzylideneacetone)dipalladium. Preference is given to bis(dibenzylideneacetone)palladium, tris(dibenzylideneacetone)dipalladium, palladium chloride, palladium bromide and palladium acetate; particular preference is given to bis(dibenzylideneacetone)palladium, palladium chloride and palladium acetate.


The amount of palladium catalyst used in the process according to the invention is 0.001 to 20 mole percent, based on substituted anthranilic acid derivative of the general formula (IV) used. Preferably 0.005 to 10 mole percent is used, more preferably 0.01 to 5 mole percent.


The phosphine ligands used in the process according to the invention are ligands of the general formula (X)





PR10R11R12   (X)


where the R10, R11 and R12 radicals are each independently hydrogen, linear or branched C1-C8-alkyl, vinyl, aryl or heteroaryl from the group of pyridine, pyrimidine, pyrrole, thiophene and furan, which may in turn be substituted by further substituents from the group of linear or branched C1-C8-alkyl or C6-C10-aryl, linear or branched C1-C8-alkyloxy or C1-C10-aryloxy, halogenated linear or branched C1-C8-alkyl or halogenated C6-C10-aryl, C6-C10 -aryloxycarbonyl, linear or branched C1-C8-alkylamino, linear or branched C1-C8-dialkylamino, C1-C8-arylamino, C1-C8-diarylamino, hydroxyl, carboxyl, cyano and halogen such as fluorine or chlorine.


Further useful phosphine ligands include chelating bisphosphines. Examples of these include 1,2-bis(diphenylphosphino)ethane, 1,2-bis(diphenylphosphino)propane, 1,2-bis(diphenylphosphino)butane, 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl and 1,1′-bis(diphenylpho sphino)ferrocene.


Preferred phosphine ligands are trialkylphosphines such as tri-tert-butylphosphine and triadamantylphosphine, and also triarylphosphines such as triphenylphosphine, tri(ortho-tolyl)phosphine or tri(para-methoxyphenyl)phosphine. Particular preference is given to triphenylphosphine.


As an alternative to this, it is also possible to use defined palladium complexes which have been obtained from the abovementioned ligands in one or more process steps.


In the process according to the invention, 1-20 molar equivalents of phosphine are used, based on the amount of palladium used. Preferably 2-15 molar equivalents are used.


Process step 2 of the process according to the invention is performed in the presence of carbon monoxide (CO). The carbon monoxide is typically introduced in gaseous form, and so the reaction is usually performed in an autoclave. It is customary to work at CO pressure 0.1 to 50 bar, preferably at 1 to 25 bar.


It is alternatively also possible in principle to introduce the carbon monoxide in the form of suitable metal carbonyl complexes, for example dicobalt octacarbonyl or molybdenum hexacarbonyl. Preference is given to working with gaseous carbon monoxide.


Process step 2 is generally performed in the presence of a base. Suitable bases are organic bases such as trialkylamines, alkylpyridines, phosphazenes and 1,8-diazabicyclo[5.4.0]undecene (DBU). Preference is given to organic bases such as triethylamine, tripropylamine, tributylamine, diisopropylethylamine, pyridine, alkylpyridines, for example 2,6-dimethylpyridine, 2-methyl-5-ethylpyridine or 2,3-dimethylpyridine.


The compounds of the general formula (V) or (VI) required for preparation of the substituted anthranilic acid derivatives of the general formula (I) are typically used in an excess, based on the substituted anthranilic acid derivative of the general formula (IV). It is also possible to use the compounds of the general formula (V) or (VI) in such an amount that they simultaneously serve as solvents.







PREPARATION EXAMPLES

The Preparation Examples which follow illustrate the invention without limiting it.


Example 1
2-Acetamido-5-cyano-3-methylbenzoic Acid



embedded image


In a 30 ml autoclave, under nitrogen as protective gas, 2.54 g [10 mmol] of N-(2-bromo-4-cyan-6-methylphenyl)acetamide, 3.89 g [21 mmol] of tri-n-butylamine, 0.131 g [0.5 mmol] of triphenylphosphine, 0.035 g [0.05 mmol] of bis(triphenylphosphine)palladium(II) chloride and 2 g of water are combined. After closure, the autoclave is purged with carbon monoxide and heated to 110° C., and a carbon monoxide pressure of 10 bar is maintained After 18 hours, the mixture is allowed to cool to room temperature, the autoclave is depressurized, the reaction mixture is stirred with methylene chloride and filtered through kieselguhr, and the filtrate is washed, first with dilute hydrochloric acid and then with water, dried over sodium sulphate and concentrated under reduced pressure. This gives 1.14 g of the title compound.


LC/MS: m/e=219 (MH+).


GC/MS(sil.): m/e=362 (M+, 2×sil., 10%), 347 (M+−15, 2×sil., 45%).


Example 2
N-(2-Bromo-4-cyano-6-methylphenyl)-1-(3-chloropyridin-2-yl)-3-{[5-(trifluoromethyl)-2H-tetrazol-2-yl]methyl}-1H-pyrazole-5-carboxamide



embedded image


To a solution of 3.74 g of 1-(3-chloropyridin-2-yl)-3-{[5-(trifluoromethyl)-2H-tetrazol-2-yl]methyl}-1H-pyrazole-5-carboxylic acid in 20 ml of acetonitrile are added 1.86 g of 3-methylpyridine. Then 1.37 g of methanesulphonyl chloride are added dropwise at 0° C. After 30 minutes at 0° C., the red solution thus obtained is slowly added dropwise to a solution of 2.11 g of 4-amino-3-bromo-5-methylbenzonitrile and 1.12 g of 3-methylpyridine in 20 ml of acetonitrile. The reaction mixture is stirred at room temperature for one hour and at 40° C. for 1 hour and cooled to room temperature, water and methylene chloride are added thereto, and the organic phase is removed, washed with dilute hydrochloric acid, dried and concentrated. The crude product thus obtained is purified by chromatography on silica gel (cyclohexane/ethyl acetate). This gives 1.30 g of the title compound as a pale beige solid.


LC/MS: m/e=566 (MH+ with 79Br and 35Cl).


Example 3
Methyl 2-({[1-chloropyridin-2-yl)-3-{[5-(trifluoromethyl)-2H-tetrazol-2-yl]methyl}-1H-pyrazol-5-yl]carbonyl}amino)-5-cyano-3-methylbenzoate



embedded image


In a 30 ml autoclave, under nitrogen as protective gas, 0.567 g of N-(2-bromo-4-cyano-6-methylphenyl)-1-(3-chloropyridin-2-yl)-3-{[5-(trifluoromethyl)-2H-tetrazol-2-yl] methyl}-1H-pyrazole-5-carboxamide, 0.463 g of tri-n-butylamine, 0.066 g of triphenylphosphine, 0.035 g of bis(triphenylphosphine)palladium(II) chloride and 10 ml of methanol are combined. After closure, the autoclave is purged with carbon monoxide and heated to 110° C., and a carbon monoxide pressure of 10 bar is maintained. After 18 hours, the mixture is allowed to cool to room temperature, the autoclave is depressurized, the reaction mixture is stirred with methylene chloride and filtered through kieselguhr, and the filtrate is washed, first with dilute hydrochloric acid and then with water, dried over sodium sulphate and concentrated under reduced pressure. This gives 0.49 g of the title compound.


LC/MS: m/e=546 (MH+ with 35Cl).


Example 4
1-(3-Chloropyridin-2-yl)-N-[4-cyano-2-(dimethylcarbamoyl)-6-methylphenyl]-3-{[5-(trifluoromethyl)-2H-tetrazol-2-yl]methyl}-1H-pyrazole-5-carboxamide



embedded image


In a 30 ml autoclave, under nitrogen as protective gas, 0.567 g of N-(2-bromo-4-cyano-6-methylphenyl)-1-(3-chloropyridin-2-yl)-3-{[5-(trifluoromethyl)-2H-tetrazol-2-yl]methyl}-1H-pyrazole-5-carboxamide, 0.463 g of tri-n-butylamine, 0.066 g of triphenylphosphine, 0.035 g of bis(triphenylphosphine)palladium(II) chloride and 2 ml of dimethylamine are combined. After closure, the autoclave is purged with carbon monoxide and heated to 110° C., and a carbon monoxide pressure of 10 bar is maintained. After 18 hours, the mixture is allowed to cool to room temperature, the autoclave is depressurized, the reaction mixture is stirred with methylene chloride and filtered through kieselguhr, and the filtrate is washed, first with dilute hydrochloric acid and then with water, dried over sodium sulphate and concentrated under reduced pressure. This gives 0.475 g of the title compound.


LC/MS: m/e=559 (MH+ with 35Cl).

Claims
  • 1. Process for preparing a compound of formula (I)
  • 2. Process according to claim 1, wherein the compound of formula (IV) is prepared by reacting a Compound of formula (IX)
  • 3. Process according to claim 2, wherein the compound of formula (IV) is prepared in the presence of a condensing agent and of a base.
  • 4. Process according to claim 1, wherein the palladium catalyst used is a palladium (II) salt and/or Pd(O) species.
  • 5. Process according to claim 4, wherein the palladium catalyst used is bis(dibenzylideneacetone)palladium, tris(dibenzylideneacetone)dipalladium, palladium chloride, palladium bromide and/or palladium acetate.
  • 6. Process according to claim 1, wherein the phosphine ligand used is a compound of formula (X) PR10R11R12   (X)where the R10, R11 and R12 radicals are each independently hydrogen, linear or branched C1-C8-alkyl, vinyl, aryl or heteroaryl selected from pyridine, pyrimidine, pyrrole, thiophene and furan, which may in turn be substituted by further substituents from the group of linear or branched C1-C8-alkyl or C6-C10-aryl, linear or branched C1-C8-alkyloxy or C1-C10-aryloxy, halogenated linear or branched C1-C8-alkyl or halogenated C6-C10-aryl, C6-C10-aryloxycarbonyl, linear or branched C1-C8-alkylamino, linear or branched C1-C8-dialkylamino, C1-C8-arylamino, C1-C8-diarylamino, hydroxyl, carboxyl, cyano and halogen,or a chelating biphosphine.
  • 7. Process according to claim 6, wherein the chelating biphosphine is one or more selected from 1,2-bis(diphenylphosphino)ethane, 1,2-bis(diphenylphosphino)propane, 1,2-bis(diphenylphosphino)butane, 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl and 1,1′-bis(diphenylphosphino)ferrocene.
  • 8. Process according to claim 6, wherein the phosphine ligand used is triphenylphosphine.
  • 9. Process according to claim 6, wherein 1-20 molar equivalents of phosphine are used, based on the amount of palladium catalyst used.
  • 10. Compound of formula (IV)
  • 11. Compound of formula (IV) according to claim 10, where R1 is optionally singly or multiply, identically or differently fluorine- or chlorine-substituted C1-C6-alkyl, or C6-C10-aryl, or is a hetaryl radical of the general formula (II)
  • 12. Compound of formula (IV) according to claim 10, where R1 is a hetaryl radical of the general formula (II)
Priority Claims (1)
Number Date Country Kind
12154290.6 Feb 2012 EP regional
PCT Information
Filing Document Filing Date Country Kind
PCT/EP2013/052350 2/6/2013 WO 00